Every lot published · search any lot number before you order

Retatrutide TRIUMPH-2 Results in Obesity and Type 2 Diabetes

TRIUMPH-2 measured body-weight change with retatrutide versus placebo in adults with type 2 diabetes and overweight or obesity. After 80 weeks, the largest average reduction across the retatrutide groups was 18.8% in the treatment-regimen analysis, compared with 5.1% in the placebo group. The peer-reviewed report provides the trial design and the estimates for all three groups.

Who took part in TRIUMPH-2. 1,152 randomized. Type 2 diabetes. Weight at week 80.GLP LIFE SCIENCES · RESEARCH NOTESWho took part in TRIUMPH-21,152 randomizedType 2 diabetesWeight at week 80

What was distinctive about the study population?

The trial randomized 1,152 adults across eight countries. Participants had a BMI of at least 27 and established type 2 diabetes. Many were already taking oral glucose-lowering medication. Background treatment matters when applying the study results, because the trial examined the effects of adding an assigned study intervention in a specific setting.

What did the weight analysis show?

The three retatrutide groups averaged reductions of 11.9%, 16.8% and 18.8% from baseline, from lowest to highest assigned group. The corresponding placebo average was 5.1%. Those figures come from one analysis approach. A sponsor announcement can quote a different percentage from the same trial when it reports a different estimand.

What should readers check about safety?

The paper reports gastrointestinal events, treatment discontinuations and other adverse events by group. In the trial, 965 of 1,152 participants completed the study drug. Check whether a quoted outcome applies to everyone assigned or to a narrower analysis population, and read the safety tables alongside weight results.

How does TRIUMPH-2 differ from TRIUMPH-1?

TRIUMPH-2 enrolled people with type 2 diabetes. TRIUMPH-1 studied a separate population without diabetes. Comparing headline numbers from the two papers cannot isolate the effect of diabetes. As of November 6, 2026, retatrutide remained investigational in the United States.

Sources and further reading

TRIUMPH-2 report in The Lancet · TRIUMPH-2 registration · FDA’s information on unapproved GLP-1 drugs

GLP Life Sciences research library · Existing TRIUMPH-1 research summary